Learn about a New
Systemic Sclerosis Clinical Trial for Your Patients

This study aims to assess the effect of an investigational drug on skin thickness in patients with systemic sclerosis (SSc) and lung involvement and function in patients with SSc-ILD.

Get Started

Zura Bio’s SSc Clinical Study

The purpose of this phase 2 study is to evaluate the effect of tibulizumab on skin thickness and disease severity in patients with SSc.

Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by any regulatory agency worldwide.

Participants must meet the following criteria:
Are between 18 and 75 years old
Have SSc, according to the American College of Rheumatology (ACR) and the European Alliance of Association for Rheumatology (EULAR) 2013 criteria
Have diffuse cutaneous SSc, defined as mRSS >0 over at least one skin area proximal to the elbows and/or knees in addition to acral fibrosis
Have had SSc (first non-RP symptom or sign attributed to SSc) for ≤7 years at time of informed consent
Have a body mass index (BMI) between 18 and 38 kg/m2
Participants are not eligible if they:
Have any current rheumatic disease other than SSc (such as rheumatoid arthritis, polymyalgia rheumatica, systemic lupus erythematosus, and polymyositis/dermatomyositis) that may interfere with assessment of SSc
Have had a renal crisis in the last 6 months
Have lung disease requiring continuous oxygen therapy
Have active Crohn’s Disease or ulcerative colitis
Used a B-cell depleting medication within the last year (prior to investigational drug dosing)  
Initiated the antifibrotics nintedanib or pirfenidone within the last 6 months (prior to investigational drug dosing). Patients who are on a stable dose for at least 6 months are allowed to participate.  

Other eligibility criteria apply and will be evaluated by a principal investigator.

Get Started

Participants will be expected to:

Visit the study site 17 times over 15 months where they will be given 2 injections once every two weeks for the first month and every four weeks after.
There is a 50% chance that participants will receive a placebo during the first period of the study.
This study includes an open-label extension period during which participants will receive the active study drug, tibulizumab.
Get Started

What this Study Offers

The study aims to evaluate the potential effect of tibulizumab on disease activity and progression in the skin and lungs of SSc patients.
‍
By enrolling in this phase 2 study, participants may receive:  

Study-related healthcare at no cost. Insurance is not required to join this study.  

Reimbursements for travel and accommodations related to study visits.

Get Started

Next Steps

If you have a patient who may be interested in this study and may be eligible, you can:  

Complete the “Contact PatientWing” form below. We’ll contact you and discuss how your patient can get involved.

Share this study with your patient so they can apply on their own. Provide them with this website For Patients & Loved Ones so they can read about the study and fill out a pre-screen questionnaire.

If you have patients who may be a good fit for the study, please contact PatientWing!

Contact PatientWing

If you have a patient who may be eligible, we would love to speak with you! Please submit the information below so our team can reach out. There is no obligation to you or your patient, by submitting this form.  
Call Us
213-459-2979
Email Us
studies@patientwing.com
Do you have a patient who may be a good fit for this study?
By clicking submit, you consent to sharing your personal data, including personal health information, with PatientWing and allowing PatientWing to collect this information and use it to contact you and respond as appropriate to your inquiry.  Please note that PatientWing will not sell your personal information or share it with third parties for marketing purposes.  For additional information on how PatientWing stores and processes personal data, please review their Privacy Policy. You will be able to unsubscribe from PatientWing communications and/or request that your information be deleted at any time.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Who's Involved?

Option Item Img
Our mission is to transform the lives of those living with severe autoimmune and inflammatory conditions by aiming to deliver breakthrough treatments that offer real hope and lasting impact.
Option Item Img
Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare and serious conditions and expertise in navigating the enrollment process, we're here for you every step of the way.

Stay Connected

Receive marketing communications from PatientWing such as patient stories and relevant clinical trial opportunities.
By clicking subscribe, you consent to PatientWing contacting you in accordance with their Privacy Policy. You will be able to unsubscribe from PatientWing communications at any time.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
A clinical study for people with SSc.
For Patients & Loved OnesContact PatientWing
© Copyright 2025 Powered by PatientWing
Privacy PolicyTerms & Conditions